Maegim한국어

국제약품

002720KOSPISector: Pharma & Biotech
₩3,330▼ 1.77%Market cap ₩70.5BAs of Jul 21, 2026 close · updated once daily
B
Grade B61.3 ptsTop 31% of 2,523 stocks
Financial strength
48.8
Growth momentum
57.3
Price attractiveness
78.3

As of Jul 21, 2026 close · This grade is not a buy/sell recommendation — it is information mechanically scored from public data using a fixed formula.

1

Financial strength

48.8
How much debt does it carry relative to equity?
Debt-to-equity ratio
86.6%
✗ Below median · Top 70.1% in sector
Sector median 51.5%
Can it cover what's due within a year?
Current ratio
108.6%
✗ Below median · Top 74.2% in sector
Sector median 191.3%
How much of revenue becomes profit?
Operating margin
3.5%
✓ Above median · Top 34.8% in sector
Sector median -2.3%
How much did it earn on its own capital?
ROE (return on equity)
5.8%
✓ Above median · Top 25.8% in sector
Sector median -4.5%

Source filing: annual report (consolidated) — view original ↗

2

Growth momentum

57.3
How much did revenue grow in a year?
Revenue growth (YoY)
12.2%
✓ Above median · Top 36.3% in sector
Sector median 6.4%
Has it grown steadily over three years?
Revenue 3-year CAGR
11.5%
✓ Above median · Top 28.3% in sector
Sector median 4.9%
Did core profits grow in a year?
Operating income change (YoY)
-7.7%
✗ Below median · Top 61.8% in sector
Sector median 3.6%
Are core profits higher than three years ago?
Operating income change (3Y)
17.3%
✓ Above median · Top 44.4% in sector
Sector median 3.5%

Source filing: annual report (consolidated) — view original ↗

3

Price attractiveness

78.3
Is the price expensive relative to earnings?
P/E (price-to-earnings)
12.4x
✓ Above median · Top 18.5% in sector
Sector median P/E of profitable peers 14.4x · 57% loss-making
Is the price expensive relative to book value?
P/B (price-to-book)
0.72x
✓ Above median · Top 25% in sector
Sector median 1.39x

Valuation uses the Jul 21, 2026 close and market cap

Grade distribution of 248 stocks in Pharma & Biotech

S1A52B66C51D61F15